Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora.

Trial Profile

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2012

At a glance

  • Drugs Moxifloxacin (Primary)
  • Indications Bacterial infections; Infectious conjunctivitis
  • Focus Pharmacodynamics
  • Sponsors Alcon
  • Most Recent Events

    • 01 Jun 2012 Actual end date Jun 2007 added as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Actual patient number (137) added as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Investigational drug changed from trimethoprim/polymixin B to moxifloxacin as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top